Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens
Open Access
Abstract
Background/Objectives: Ovarian cancer is the fifth most common cancer among women, with an estimated 19,680 new cases projected in 2024. Adjuvant chemotherapy remains the standard treatment for epithelial ovarian cancers but is frequently associated with adverse events, such as chemotherapy-induced alopecia (CIA). CIA is a particularly distressing side effect that significantly affects the body image, self-esteem, and quality of life of patients. Unfortunately, CIA remains underexplored in patients with ovarian cancer. Methods: This scoping review analyzed PubMed- and EMBASE-indexed studies investigating the incidence, severity, and mechanisms of CIA in ovarian cancer patients. Eighteen studies were included for analysis. Results: Our analysis identified platinum-based compounds, taxanes, and topoisomerase I inhibitors as the agents most strongly correlated with severe alopecia, particularly in combination regimens such as carboplatin–paclitaxel (CP), and cyclophosphamide, adriamycin, and cisplatin (CAP). Among the monotherapies, taxanes, including paclitaxel and docetaxel, posed the highest risk of CIA. Mild-to-moderate alopecia was observed in patients treated with gemcitabine or pegylated liposomal doxorubicin. Alternative factors such as dosing schedules and prior chemotherapy exposure also significantly influence CIA severity. Conclusions: Given the profound psychosocial impact of CIA, optimizing treatment protocols to reduce the severity of alopecia without compromising therapeutic efficacy is crucial. These findings offer insights that may guide future therapeutic strategies for improving patient outcomes and quality of life.Keywords
This publication has 60 references indexed in Scilit:
- Hair loss during and after breast cancer therapySupportive Care in Cancer, 2023
- A review of co-registered transvaginal photoacoustic and ultrasound imaging for ovarian cancer diagnosisCurrent Opinion in Biomedical Engineering, 2022
- Hair disorders in patients with cancerJournal of the American Academy of Dermatology, 2019
- Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cellsCellular and Molecular Life Sciences, 2018
- Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveCancer Chemotherapy and Pharmacology, 2016
- Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancerCochrane Database of Systematic Reviews, 2013
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological featuresVirchows Archiv, 2012
- Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature reviewPsycho-Oncology, 2007
- Pathology and classification of ovarian tumorsCancer, 2003
- Paclitaxel-induced cell deathCancer, 2000